Assembly Biosciences Inc - Asset Resilience Ratio
Assembly Biosciences Inc (ASMB) has an Asset Resilience Ratio of 87.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Assembly Biosciences Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Assembly Biosciences Inc's Asset Resilience Ratio has changed over time. See Assembly Biosciences Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Assembly Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Assembly Biosciences Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $210.02 Million | 87.51% |
| Total Liquid Assets | $210.02 Million | 87.51% |
Asset Resilience Insights
- Very High Liquidity: Assembly Biosciences Inc maintains exceptional liquid asset reserves at 87.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Assembly Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Assembly Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Assembly Biosciences Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Assembly Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 61.87% | $73.73 Million | $119.17 Million | -18.82pp |
| 2023-12-31 | 80.69% | $110.41 Million | $136.82 Million | +42.19pp |
| 2022-12-31 | 38.50% | $39.19 Million | $101.79 Million | -14.36pp |
| 2021-12-31 | 52.86% | $101.00 Million | $191.06 Million | -2.55pp |
| 2020-12-31 | 55.42% | $156.97 Million | $283.25 Million | -9.92pp |
| 2019-12-31 | 65.34% | $227.31 Million | $347.89 Million | -0.55pp |
| 2018-12-31 | 65.89% | $176.61 Million | $268.05 Million | +43.49pp |
| 2017-12-31 | 22.39% | $37.91 Million | $169.30 Million | -2.46pp |
| 2016-12-31 | 24.86% | $24.39 Million | $98.12 Million | -5.47pp |
| 2015-12-31 | 30.32% | $40.56 Million | $133.74 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $71.23 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $27.13 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $20.56 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $37.05 Million | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepat… Read more